Journal of ethnopharmacology · 2026
NaRu-3 ameliorates experimental rheumatoid arthritis via MAPK pathway inhibition.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Lingfeng, Yu Chao, Zhang Minjie, Wang Rui, Chen Yanchi, Zhang Xiaoshan, Wei Ying, Wang Yaxi
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: NaRu-3 is a traditional Mongolian multi-component formula widely used for rheumatoid arthritis (RA), but its pharmacological mechanism remains unclear.
AIM OF THE STUDY: To elucidate the molecular basis of NaRu-3 against RA.
MATERIALS AND METHODS: Major bioactive constituents of NaRu-3 were characterized by chemical fingerprinting. Therapeutic efficacy was evaluated in collagen-induced arthritis mice using clinical scores and [18F]FDG PET/CT to quantify inflammatory activity in the joints. Cytokine assays together with hepatic and renal histopathology, were assessed to evaluate the safety of NaRu-3. Transcriptomic profiling of ankle tissue was performed to identify key pathways, followed by functional and protein validation in lipopolysaccharide-stimulated MH7A synoviocytes and HUVECs.
RESULTS: Eighty-seven compounds were identified. NaRu-3 significantly alleviated arthritis severity and reduced SUVmax, and decreased the serum TNF-α, IL-1β, IL-6, and VEGF-A levels. Histological analyses revealed diminished synovial hyperplasia and cartilage erosion, increased COL-2 deposition in cartilage, and reduced IL-6, TNF-α, and VEGF expression in synovial tissue without evident hepato- or nephrotoxicity. Transcriptomic analysis revealed coordinated regulation of extracellular matrix remodeling and inflammation, with significant enrichment of the MAPK pathway. HMGB1, ERK, p38, COX-2 and MMP-3 were markedly downregulated. In vitro, NaRu-3 inhibited proliferation, migration and angiogenic activity of synoviocytes and endothelial cells.
CONCLUSIONS: NaRu-3 attenuates experimental arthritis by suppressing MAPK-mediated inflammatory and matrix-remodeling signaling, thereby inhibiting synovial hyperplasia, angiogenesis, and cartilage damage. These findings provide mechanistic support for NaRu-3 as a promising multi-target therapeutic candidate to treat RA.
AIM OF THE STUDY: To elucidate the molecular basis of NaRu-3 against RA.
MATERIALS AND METHODS: Major bioactive constituents of NaRu-3 were characterized by chemical fingerprinting. Therapeutic efficacy was evaluated in collagen-induced arthritis mice using clinical scores and [18F]FDG PET/CT to quantify inflammatory activity in the joints. Cytokine assays together with hepatic and renal histopathology, were assessed to evaluate the safety of NaRu-3. Transcriptomic profiling of ankle tissue was performed to identify key pathways, followed by functional and protein validation in lipopolysaccharide-stimulated MH7A synoviocytes and HUVECs.
RESULTS: Eighty-seven compounds were identified. NaRu-3 significantly alleviated arthritis severity and reduced SUVmax, and decreased the serum TNF-α, IL-1β, IL-6, and VEGF-A levels. Histological analyses revealed diminished synovial hyperplasia and cartilage erosion, increased COL-2 deposition in cartilage, and reduced IL-6, TNF-α, and VEGF expression in synovial tissue without evident hepato- or nephrotoxicity. Transcriptomic analysis revealed coordinated regulation of extracellular matrix remodeling and inflammation, with significant enrichment of the MAPK pathway. HMGB1, ERK, p38, COX-2 and MMP-3 were markedly downregulated. In vitro, NaRu-3 inhibited proliferation, migration and angiogenic activity of synoviocytes and endothelial cells.
CONCLUSIONS: NaRu-3 attenuates experimental arthritis by suppressing MAPK-mediated inflammatory and matrix-remodeling signaling, thereby inhibiting synovial hyperplasia, angiogenesis, and cartilage damage. These findings provide mechanistic support for NaRu-3 as a promising multi-target therapeutic candidate to treat RA.